Methodology: R&D Productivity Ranking
To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion's methodology takes an approach that focuses on value.
You may also be interested in...
Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.
An analysis of the R&D productivity of the world’s 30 largest public pharmaceutical companies reveals an overall drop in R&D productivity, but this should not hide the fact that some companies are still performing extremely well.
Catenion, a biopharma-focused R&D strategy consulting firm, has analyzed the performance of the top-30 biopharma companies in 2018 and outlined major concerns for the future of innovation in drug development.